Skip Navigation


JAC Advance Access originally published online on January 25, 2006
Journal of Antimicrobial Chemotherapy 2006 57(3):562-565; doi:10.1093/jac/dkl003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/3/562    most recent
dkl003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sahly, H.
Right arrow Articles by Podschun, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahly, H.
Right arrow Articles by Podschun, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Activity of human ß-defensins 2 and 3 against ESBL-producing Klebsiella strains

Hany Sahly1,*, Sabine Schubert1, Jürgen Harder2, Michael Kleine3, Dorthe Sandvang4, Uwe Ullmann1, Jens M. Schröder2 and Rainer Podschun1

1 Institute of Infection Medicine, Faculty of Medicine, University of Kiel, Brunswiker Strasse 4, 24105 Kiel, Germany; 2 Clinical Research Unit, Department of Dermatology, Medical School, University of Kiel, Schittenhelmstrasse 7, 24105 Kiel, Germany; 3 PLANTON GmbH, am Kiel-Kanal 44, 24106 Kiel, Germany; 4 National Centre for Antimicrobials and Infection Control, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark

Received 4 August 2005; returned 27 October 2005; revised 6 December 2005; accepted 23 December 2005

* Corresponding author. Tel: +49-431-597-3316; Fax: +49-431-597-3296; E-mail: sahly{at}infmed.uni-kiel.de

Objectives: To test the bactericidal activity of human ß-defensins (hBDs) 2 and 3 against extended-spectrum ß-lactamase (ESBL)-producing Klebsiella strains.

Methods: Thirty-six Klebsiella pneumoniae and seventeen Klebsiella oxytoca ESBL-producing isolates from nosocomial infections were tested. The bactericidal activity of recombinantly synthesized hBD-2 and -3 was tested and the results were given either as lethal doses killing ≥90% of bacteria (LD90s) or as MBCs (≥99.9% killing).

Results: Except for one intermediately susceptible strain (MBC = 25 mg/L), all other ESBL-producing strains were highly susceptible to both defensins (LD90s and MBCs ≤ 12.5mg/L).

Conclusions: The results underline the high efficacy of hBD-2 and -3 against ESBL-producing Klebsiella, making both defensins attractive candidates as antimicrobial agents to combat these increasingly troublesome bacteria.

Keywords: multidrug resistance , innate immunity , Klebsiella spp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
C. H. Serezani, J. Chung, M. N. Ballinger, B. B. Moore, D. M. Aronoff, and M. Peters-Golden
Prostaglandin E2 Suppresses Bacterial Killing in Alveolar Macrophages by Inhibiting NADPH Oxidase
Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 562 - 570.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.